Meril Life Sciences, a global medical devices company has introduced Myval in India; the first ever indigenously designed and manufactured Transcatheter Aortic Heart Valve (TAVR). This treatment modality is usually beneficial to those who are apprehensive on getting an open heart valve replacement surgery or is at a higher risk of heart disease. TAVR is a minimally invasive procedure where the doctor places an artificial replacement valve in the patient’s diseases valve via a catheter that is inserted through the femoral artery (the large artery in the groin). Some patients do not respond well to a traditional open-heart surgery, TAVR is an alternative way to replace the unhealthy valves.
Sanjeev Bhatt, VP Corporate Strategy, Meril Life Sciences said, "Meril is the first Indian company to commercially make this therapy available in the country. Through the commercialization of this technology, Meril will soon bring the next generation treatment modality to thousands of patients across the country and globally." Bhatt also adds, "The novel Myval technology is associated with zero new pacemaker implantation rates post procedure (which is an important benefit for the patient already treated for valve replacement). A pacemaker is an additional device that may be placed post TAVR procedure.” He also assured that the price of this particular technology will be within an affordable rage keeping in mind healthcare for all.
The Principal Investigator and Chairman of Fortis Escorts Heart Institute Ashok Seth has positive hopes from this device as he said, "The development of this valve, which is implanted non-surgically through a catheter is a great achievement for the 'Made in India' initiative that such an important R&D has happened from India in a field which till now has been dominated by only American devices.”
‘Myval’ TAVR technology is like a boon to millions suffering from aortic stenosis for an improved productivity of life and is considered a better alternative to a traditional surgical procedure as it has a shorter recovery time as well.
There had been clinical trials of the device and patients have responded really well to this treatment with no significant cardiac, cerebral and renal issues within the 6-month follow-up checkup after the treatment. The first patient who had received the Myval treatment completed one and a half years of good health and a symptom-free productive life.
Based on these clinical trials, the device has received an approval from Indian drug regulator Central Drugs Standard Control Organisation (CDSCO) for its commercialization.
Sanjeev Bhatt is all praises for this proud moment of approval commenting, “Meril has always been dedicated towards design and development of novel, clinically relevant, state-of-the-art and best-in-class devices to alleviate human suffering and improve quality of life. The launch of indigenously developed Myval Transcatheter Heart Valve technology is an assertion of this fundamental belief. For us, it is a proud moment to be the first Indian company to commercially make this therapy available in the country.”